Latest news with #cancer treatment
CTV News
20 hours ago
- Health
- CTV News
‘Helps me greatly': Alberta team explores exercise benefits for cancer patients
An Alberta team is studying how exercise after—and even during—cancer treatments can provide survival benefits. Results will be released soon. An Alberta team is studying how exercise after—and even during—cancer treatments can provide survival benefits. Results will be released soon. Study on exercise after and during cancer treatment looking positive An Alberta team is studying how exercise after—and even during—cancer treatments can provide survival benefits. Alberta Community Exercise (ACE) programs have been held throughout the province since 2017, and the research team is expected to release results soon from its study of more than 2,500 participants. Some participants are already touting the benefits. 'Very helpful, and it's very important that they are here to guide us to do the exercises that are good for us individually,' said two-time breast cancer survivor Lynne Farley of Calgary. Two-time breast cancer survivor Lynne Farley. Two-time breast cancer survivor Lynne Farley. Research is already revealing promising data about exercise programs in oncology treatment, including an 18-year study on colon cancer patients from all over the world recently published in the New England Journal of Medicine. 'Hard data showing the survival benefits of exercise and those benefits, they're comparable to what you would see with some of the drug treatments,' said Dr. Nicole Culos-Reed, a University of Calgary kinesiology professor and founder of Alberta Community Exercise (ACE). This information is validating but not surprising for Culos-Reed, who started the ACE program for people with all kinds of cancer. 'It's not just early stage; we're seeing metastatic disease … really higher-risk cancers like neural oncology brain tumours,' said Culos-Reed. Participants range from recent post-cancer to those waiting for or in the middle of treatment. A specially trained team helps tailor exercises for individual needs and abilities. 'We've had people contact, and they say, 'I have a walker; can I do your program?' And I think at first it was like, I don't know—let's try it out and see, and then we can get these people into the class.' said Jessica Danyluk, a clinical exercise physiologist with ACE. Alberta Community Exercise founder Dr. Nicole Culos-Reed, two-time breast cancer survivor Lynne Farley and clinical exercise physiologist Jessica Danyluk. Alberta Community Exercise founder Dr. Nicole Culos-Reed, two-time breast cancer survivor Lynne Farley and clinical exercise physiologist Jessica Danyluk. The social side of the class is just as important. 'Just being able to talk to people in the same situation as I am just helps me greatly,' said Farley. People who qualify for ACE get the first 12 weeks free thanks to donors, but continued programs cost participants about $7 a class. The program isn't currently funded by the province, but people involved with ACE hope that changes. 'Because people need it. It will help them build confidence, build strength, empower them,' said Danyluk. All of which is vital for people who have faced a lack of control due to disease. 'You've got to keep going—do these programs. Live each day and make the most of each day,' said Farley.
BBC News
2 days ago
- Health
- BBC News
PD Jura: 'Profound shock' as Leicestershire police dog dies
A police dog who shared a "remarkable bond" with his handler, who was having cancer treatment during their training, has died after falling ill while off Jura died aged five after having emergency surgery for a suspected case of gastric torsion on Friday, Leicestershire Police force said the dog had fallen ill on Wednesday afternoon and was immediately taken to the vet by handler PC Darren social media, the force's dogs section said Jura's loss had come as "a profound shock" and colleagues had lost "a treasured member of our team". In a statement, the force said: "Initially there was hope that PD Jura would recover but sadly he passed away on Friday."PD Jura was a much-loved member of our policing family and an exceptional police dog." Jura was just a few weeks old when he started his initial training in 2020 with PC Sewell in 2020, who had been diagnosed with stage 4 work together saw PC Sewell given a Special Recognition Award by the Thin Blue Paw Foundation, a charity which supports serving and retired police became a fully-fledged member of the force's dog section in 2021 and along with PC Sewell, "had outstanding operational success".The statement added: "We want to thank PD Jura for his service to the force and the communities we serve. He will be deeply missed by so many."A spokesperson for the Thin Blue Paw Foundation said Jura had a "remarkable bond" with PC Sewell, and the training sessions "provided a welcomed escape for Darren while undergoing chemotherapy treatment".PC Sewell was by Jura's side when he died, the charity added.
Reuters
2 days ago
- Business
- Reuters
Sino Biopharmaceutical to acquire LaNova Medicines for up to $951 million
July 15 (Reuters) - Hong Kong-listed Sino Biopharmaceutical ( opens new tab said on Tuesday it will buy the remaining 95.09% stake it does not hold in Shanghai-based LaNova Medicines for no more than $950.92 million. The acquisition of the cancer treatment developer will enhance Sino's competitiveness and influence in oncology innovation, while also enabling potential future international transactions by leveraging LaNova's R&D capabilities, it added. Sino added LaNova will become an indirect wholly owned subsidiary once the deal is completed, which is expected within 30 business days after regulatory conditions are met. The firm had already bought a 4.91% stake in LaNova in November, opens new tab last year, paying around 142 million yuan ($19.80 million) at the time. LaNova Medicines was founded in 2019, specialising in discovering and developing antibody-based cancer treatments, according to details mentioned on their website. In November last year, Merck (MRK.N), opens new tab licensed an early-stage cancer drug LM-299 from LaNova in a deal worth up to $3.3 billion, taking over its development. The drug candidate targets the PD-1 protein, which prevents the immune system from killing cancerous cells. It also curbs levels of VEGF protein, which can encourage tumor growth if found in excess. ($1 = 7.1729 Chinese yuan renminbi)
CBS News
3 days ago
- Health
- CBS News
Breakthroughs in cancer treatment spare Long Island teen from leg amputation
Breakthroughs in a rare cancer treatment are helping a New York woman conquer an aggressive bone tumor. Doctors at Cohen Children's Medical Center say a state-of-the-art surgery for osteosarcoma means the Long Island college student's leg will not have to be amputated. A devastating diagnosis Kelly Mullooly, a University of New Haven honors college freshman and student-athlete, presumed her constant knee pain was from too many gym workouts and rigorous cheer team activities. After the Massapequa-native started feeling it in December, doctors initially advised physical therapy. But nothing helped and she knew something wasn't right. "It was a very overwhelming time and a very scary time," she said. While home for spring break, Mullooly and her family insisted on more medical testing. They sought doctors at a different hospital -- Cohen Children's Medical Center. She went there for an MRI and doctors came back with devastating news. "That same day they found the tumor, and from there everything has just been a complete whirlwind," Mullooly said. "So fast-moving, with biopsies and doctors appointments, and within that week I was diagnosed with osteosarcoma." "Because this is a very aggressive tumor, we have to move very quickly with chemotherapy and treatment," Dr. Carolyn Fein Levy, of Cohen Children's Medical Center, said. Life-altering decisions and surgery Crissy Mullooly said she was in awe of her daughter, who remained brave and stoic while having to make life-altering decisions. "It's amazing because it's a lot to ask an 18-year-old at the time, now she's 19, to have gone through," she said. As part of the treatment, Mullooly underwent future fertility planning in which her eggs were harvested prior to chemotherapy. "They immediately had a plan for me and that was very comforting," she said. "She had what is called limb-sparing surgery where we take out a piece of the bone and replace with a prostheses in order to save her leg," Levy said. Mullooly's cancerous bone was removed and replaced with a metal knee. The surgery also saved her life. "We want her to be able to live the rest of her life without a sarcoma, without any cancer and to be able to do everything she wants to do," Dr. Howard Goodman said. "Not that everything will go back to normal, but everything will be a new normal," Mullooly said. As she completes chemotherapy, she's filled with optimism and ready to rejoin UNH and the cheer team later next year. Before limb-sparing surgery, a patient with osteosarcoma would have needed their leg amputated. They also would have continued living with the risk of the cancer returning.
Yahoo
4 days ago
- Health
- Yahoo
Cancer treatment ‘revolution' on the horizon, says leading doctor
Cancer treatment is on the "cusp of a golden era", according to NHS England's outgoing national medical director, Professor Sir Stephen Powis. He expects that the development of drugs harnessing the body's immune system to fight the disease will bring "great advances in cancer survival". In his final interview before retiring, Sir Stephen, 64, told The Times: 'We are at the cusp of a golden era in terms of the way we treat a range of cancers. 'For many cancers now, people should be confident that it's not a death sentence and that more treatments will become available.' He said the rise in people living longer and surviving cancers would continue, alongside cures for some forms of the disease. 'Our understanding of the genetics of cancer, of the way we can target cancers with particular drugs, and how we can use the body's own immune system to target cancers itself, is being revolutionised,' he said. He compared the progress made in treating cancer with the success in developing HIV/Aids treatments since he qualified as a doctor 40 years ago. He also said an increased focus on prevention will help eliminate certain types of cancer. 🧵Today is my last day working at NHS England. It has been an honour to serve as National Medical Director for the last seven and a half years. Thank you to everybody who has supported and encouraged me over the years. — Professor Stephen Powis (@NHSEnglandNMD) July 10, 2025 'We can't prevent all cancers, but there are cancers that we can certainly prevent,' he said, adding that he hopes lung cancers will become 'a lot rarer'. Cancer treatment, he said, would be 'driven by genetics' to become more individualised with the increased ability to pinpoint mutations in cells. His comments come as experts warned of a 'postcode lottery' in cancer services that focus on improving patients' quality of life and providing urgent care for people with the disease. The Royal College of Physicians (RCP), the Royal College of Radiologists (RCR), the UK Association of Supportive Care in Cancer (UKASCC) and the Association for Palliative Medicine (APM) have called for urgent investment in supportive and acute oncology. Sir Stephen warned the biggest challenge facing the NHS was the rise in elderly people and the economic pressure that is putting on the younger generation and the economy. Last week, Sir Stephen warned the British Medical Association (BMA) to 'think really hard' about whether industrial action by resident doctors – formerly junior doctors – planned for later this month is justified. He told The Times the walkout would cause 'tens of thousands of appointments and procedures' to be cancelled. The kidney specialist has served as national medical director since January 2018 and held the role throughout the Covid pandemic.
